RT Journal Article
SR Electronic
T1 EGFR-Activating Mutations Are Not Present in Breast Tumors of Japanese Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4219
OP 4222
VO 30
IS 10
A1 URAMOTO, HIDETAKA
A1 SHIMOKAWA, HIDEHIKO
A1 NAGATA, YOSHIKA
A1 ONO, KENJI
A1 HANAGIRI, TAKESHI
YR 2010
UL http://ar.iiarjournals.org/content/30/10/4219.abstract
AB Background: Despite advances in treatment, recurrent breast cancer remains a lethal disease. The epidermal growth factor receptor family has been suggested to play a role in breast cancer. However, no investigations of the frequency of EGFR mutation and the potential role of EGFR tyrosine kinase inhibitor (TKI) in Japanese patients with breast cancer. Materials and Methods: Tumor specimens were collected from 84 breast cancer patients who underwent surgery. Polymerase chain reaction-based methods were used to examine EGFR-activating mutations (exon 19 and 21). Results: Activating mutations in the tyrosine kinase domain of EGFR were not identified in any of the tumors. Conclusion: EGFR-activating mutations were not present in the Japanese breast cancer series studied here. Therefore, unlike lung cancer, EGFR tyrosine kinase inhibitors are unlikely to provide any benefit for Japanese breast cancer patients.